



Panacea Biotec
Innovation in support of life

Statement of standalone unaudited financial results for the quarter ended June 30th, 2013

(Rs. in Lacs)


Particulars	For quarter ended			For year ended
	30.06.2013	31.03.2013	30.06.2012	31.3.2013
	Unaudited	Audited(refer note no 10)	Unaudited	Audited
PART - I				
1. Income from operations				
a. Net sales / income from operations (net of excise duty)	10,446	18,437	8,310	53,042
b. Other operating income	1,317	599	558	6,550
Total income from operations (net)	11,763	19,036	8,868	59,592
2. Expenditure				
a. Cost of materials consumed	6,390	4,635	1,909	23,637
b. Purchase of stock in trade	689	554	508	2,326
c. (Increase)/Decrease in inventories	(3,139)	5,091	567	29
d. Employees benefits expense	3,672	3,471	3,437	13,723
e. Depreciation and amortisation expense	1,896	2,102	2,000	8,354
g. Other expenses	5,064	7,229	4,313	26,333
Total expenses	14,572	23,082	12,734	74,402
3. (Loss)/Profit from operations before other income, finance cost, foreign exchange fluctuation gain/ (loss) & exceptional items (1-2)	(2,809)	(4,046)	(3,866)	(14,810)
4. Other income	25	272	12	543
5. (Loss)/Profit from ordinary activities before finance cost, foreign exchange fluctuation gain / (loss) & exceptional items (3+4)	(2,784)	(3,774)	(3,854)	(14,267)
6. Finance cost	3,212	3,570	2,751	10,574
7. Foreign exchange fluctuation loss/ (gain)	96	(126)	1,371	805
8. (Loss)/Profit from ordinary activities after finance cost before exceptional items (5-6-7)	(6,092)	(7,218)	(7,976)	(25,646)
9. Exceptional income/(exp)	-	(1,057)	-	583
10. Profit / (loss) from ordinary activities before tax (8+9)	(6,092)	(8,275)	(7,976)	(25,063)
11. Tax expenses	-	-	(1,379)	(2,050)
12. Net profit / (loss) from ordinary activities after tax (10-11)	(6,092)	(8,275)	(6,597)	(23,013)
13. Extraordinary items (net of tax expenses)	-	-	-	-
14. Net profit / (loss) for the period (12-13)	(6,092)	(8,275)	(6,597)	(23,013)
15. Paid up equity share capital (face value of Re.1 per share)	613	613	613	613
16. Reserves excluding revaluation reserves	-	-	-	18,282
17. Earning per share (EPS)	(9.95)	(13.51)	(10.77)	(37.57)
- Basic (in Rs.)	(9.95)	(13.51)	(10.77)	(37.57)
- Diluted (in Rs.)	(9.95)	(13.51)	(10.77)	(37.57)
PART - II				
A. Particulars of shareholding				
1. Public shareholding				
- No. of shares	15,427,192	15,427,192	15,426,992	15,427,192
- Percentage of shareholding	25.19	25.19	25.19	25.19
2. Promoters and promoter group Shareholding				
a) Pledge / encumbered				
- No. of shares	-	-	-	-
- % of Shares (as a % of the total shareholding of promoter & promoter group)	-	-	-	-
- % of Shares (as a % of the total share capital of the Company)	-	-	-	-
b) Non-encumbered				
- Number of shares	45,823,554	45,823,554	45,823,754	45,823,554
- % of Shares (as a % of the total shareholding of promoter & promoter group)	100.00	100.00	100.00	100.00
- % of Shares (as a % of the total share capital of the Company)	74.81	74.81	74.81	74.81

B. Investor complaints	
Pending at the beginning of the quarter	-
Received during the quarter	-
Disposed of during the quarter	-
Remaining unresolved at the end of the quarter	-

Unaudited Segment-wise Revenue , Results, and Capital Employed for the quarter ended on 30.06.2013

Particulars	For quarter ended			For year ended
	30.06.2013	31.03.2013	30.06.2012	31.3.2013
	Unaudited	Audited(refer note no 10)	Unaudited	Audited
1. Segment revenue				
(a) Vaccines	2,804	8,956	593	17,682
(b) Formulations	8,158	9,815	8,176	38,546
(c) Research & development	798	-	-	2,717
(d) Unallocated	3	265	99	647
Gross sale/Income from operation	11,763	19,036	8,868	59,592
Less : Inter segment revenue	-	-	-	-
Net sales/income from operations	11,763	19,036	8,868	59,592
2. Segment results				
Profit (+)/ loss (-) before tax and interest from each segment				
(a) Vaccines	(1,411)	(1,604)	(2,274)	(9,456)
(b) Formulations	1,419	219	2,002	8,375
(c) Research & development	(1,460)	(2,668)	(1,767)	(7,712)
Total	(1,452)	(4,053)	(2,039)	(8,793)
Less : i) Finance cost	3,212	3,570	2,751	10,574
ii) Other un-allocated expenditure net off un-allocated income	1,427	652	3,186	5,696
Total profit before tax	(6,092)	(8,275)	(7,976)	(25,063)
3. Capital Employed				
(Segment assets-segment liabilities)				
(a) Vaccines	55,354	55,595	72,374	55,595
(b) Formulations	25,226	26,251	30,370	26,251
(c) Research & development	18,533	19,548	24,411	19,548
(d) Unallocated	(50,491)	(45,268)	(52,820)	(45,268)
Total capital employed	48,622	56,126	74,335	56,126

Handwritten signature and date: 08/08/2013



Notes:

- 1 The above financial results were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their meetings held on August 7, 2013 and August 8, 2013 respectively.
- 2 Tax expense includes income tax and deferred tax (charge)/credit.
- 3 The Company's Share Transfer Books and Register of Members will remain closed from Thursday, September 19, 2013 to Wednesday, September 25, 2013 (both days inclusive) for the purpose of Annual General Meeting scheduled to be held on September 25, 2013.
- 4 During the quarter, the Company has launched four new products namely **Epotrust 6000 PFS** (Renal failure), **Alphadol 0.5 mcg** (renal bone diseases & rickets), **Ilaone** (dyspepsia, peptic ulcer disease), **Grafmet 500 mg Inj** (arthritis, skin, blood, kidney, eye, thyroid and intestinal).
- 5 During the quarter, an amount of US\$ 2.92 million (Rs.1,593 Lac) has been received from the Company's wholly owned subsidiary, Rees Investments Limited, Guernsey, as a part repayment of loan granted to it in earlier years.
- 6 During the quarter, the Company has given Rs.566 Lac as advance share application money to its Indian subsidiary viz. NewRise Healthcare Pvt. Ltd. and has made an equity investment of Rs.2.5 Lac in its Joint Venture, Adveta Power Pvt. Ltd.
- 7 As regards Auditors' observations in their report on the audited accounts for the Financial Year 2012-13 and in their limited review report on the above results:
 - i) Due to the absence of profits during the financial year 2012-13, the total remuneration of the Managing/Joint Managing and Whole Time Director had exceeded the ceiling prescribed in Section II of Part II of Schedule XIII to the Companies Act, 1956. Accordingly, applications for protection/approval of the Central Government in respect of excess remuneration for financial years 2012-13 have been filed and requisite approval is awaited.
 - ii) During the year ended March 2011-12, World Health Organization (WHO) had delisted Company's DTP-based combination vaccines from its list of pre-qualified vaccines. During the month of February, 2013 Auditors from WHO and UNICEF visited the Company's vaccine facilities at Lalru (Punjab) and Baddi (H.P.) with the objective of re-evaluation of the acceptability in principle of combination vaccines (DTP-Hep B-Hib) produced by Panacea Biotech for purchase by United Nations Agencies. During the current quarter, the Company has completed implementation of Corrective and Preventive Action (CAPA) subsequent to the visit by WHO auditors and also submitted additional data pertaining to product's stability studies to WHO. The Company has a stock of Rs.2,093 lacs and Rs.6,394 lacs of raw & packing material and finished goods, respectively as at June 30, 2013 pertaining to these vaccines. Fixed assets relating to above products cannot be quantified separately. The Company is confident that with the post audit activities, it will be able to get re-listing of combination vaccines in the list of WHO pre-qualified vaccines in due course and would do its best to use/sell/liquidate these stocks in domestic and international markets.
During the current quarter, the Company has incurred net losses of Rs.6,092 lacs mainly because of delisting of its vaccine products from the list of pre-qualified vaccines. However, the Company's cash flow projections show that credit facilities from banks and internal accruals would be sufficient to meet the working capital and other liquidity requirements associated with the existing operations.
- 8 As regards Auditors' observations in their limited review report on the above results, that the managerial remuneration of Rs.92.4 lacs paid during the current quarter may exceed the limits specified under relevant provisions of the Companies Act, 1956, on account of losses incurred during the current quarter, the Company has filed requisite applications for obtaining approval from Central Government for excess remuneration, if any, in the event of inadequate profits/ losses during the current financial year ending March 31, 2014.
- 9 The necessary certificate in respect of the above results in terms of requirement of clause 41 of the listing agreement, has been placed before the Board of Directors.
- 10 The figure of the quarter ended 31st March 2013 are the balancing figures between audited figures in respect of the full financial year 2012-2013 and published year to date figures upto the third quarter of previous financial year 2012-2013.
- 11 Previous period / year figures have been regrouped/ reclassified to make them comparable with those of current Quarter.
- 12 The above results are also available on the Company's website viz. <http://www.panaceabiotec.com>.

For and on behalf of the Board

New Delhi
August 8, 2013

Dr. Rajesh Jain
Joint Managing Director

Panacea Biotech Limited

Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab

